Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2025)
Legend Biotech (LEGN) reported Cash from Financing Activities of -$600000.0 for Q4 2025, down 100.0% on a YoY basis from -$inf billion in Q4 2024, and down 189.55% quarter-over-quarter from $670000.0 in Q3 2025.
Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Legend Biotech has reported Cash from Financing Activities for 7 years, with the latest figure at -$600000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 100.0% year-over-year to -$600000.0; the trailing twelve-month figure through Dec 2025 stood at -$253000.0 (down 104.41% YoY), and the FY2025 full-year result was -$300000.0, down 105.26% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at -$600000.0, down from $670000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $790.0 million in Q2 2023, with the low at -$990000.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $90.1 million across 5 years, with a median of $878000.0 in 2023.
- The largest YoY upside for Cash from Financing Activities was 78200.1% in 2023 against a maximum downside of 1876.0% in 2023.
- Legend Biotech's Cash from Financing Activities stood at $323.6 million in 2021, then sank by 100.24% to -$783000.0 in 2022, then surged by 218.14% to $925000.0 in 2023, then plunged by 132.43% to -$300000.0 in 2024, then sank by 100.0% to -$600000.0 in 2025.
- The last three Cash from Financing Activities figures came in at -$600000.0 (Q4 2025), $670000.0 (Q3 2025), and -$990000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | -802.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -600,000.00 |
| Dec 31, 2025 | -600,000.00 |
| Sep 30, 2025 | 670,000.00 |
| Sep 30, 2025 | 670,000.00 |
| Jun 30, 2025 | -990,000.00 |
| Jun 30, 2025 | -990,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Sep 30, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 955,000.00 |
| Jun 30, 2024 | 955,000.00 |
| Mar 31, 2024 | 831,000.00 |
| Mar 31, 2024 | 831,000.00 |
| Dec 31, 2023 | 925,000.00 |
| Dec 31, 2023 | 925,000.00 |
| Sep 30, 2023 | 961,000.00 |
| Sep 30, 2023 | 961,000.00 |